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Objectives: This study evaluated the incidence and outcomes of
secondary procedures for Type I endoleaks following endovascular aneu-
rysm repair (EVAR).
Methods: From 2002 to 2013, 2496 patients underwent EVAR for
treatment of nonruptured (n ¼ 2315; 93%) and ruptured (n ¼ 181; 7%)
abdominal aortic aneurysms (AAAs). Postoperative follow-up included clin-
ical examination, ultrasound, and computed tomography at 1, 6, and 12
months, and yearly thereafter. Patients with Type I endoleaks were either
observed without any intervention, underwent endovascular interventions,
or surgical explant. Data was prospectively collected.
Results: Of 2496 patients that underwent EVAR, over a mean follow-
up of 57 months, 202 (8%) patients were discovered to have Type I endo-
leaks from proximal (n ¼ 111; 55%), distal (n ¼ 69; 34%), or proximal and
distal (n ¼ 22; 11%) stent graft ﬁxation sites. The mean age was 74 years,
and the maximum AAA diameter was 6.0 cm. Indications for treatment
included asymptomatic Type I endoleaks (n ¼ 171; 85%), symptomatic
aneurysms (n ¼ 14; 7%), or aneurysm rupture (n ¼ 17; 8%). In 49 (24%)
patients, Type I endoleaks resolved without any further intervention. Treat-
ments included embolization procedures only in 17 (8%), stent graft exten-
sions only in 103 (51%), embolization and stent graft extensions in 19 (9%),
and stent graft explant in 14 (7%). Multiple endovascular procedures were
required in 41 (20%) patients. Overall operative mortality for all Type I
endoleaks was 1.5%; all deaths occurred in patients that presented with
ruptured AAAs (3/17; 18%).
Conclusions: Our single center long-term EVAR experience indicates
that 8% of patients developType I endoleaks. The vastmajority of Type I endo-
leaks can be treated by endovascular means with limited mortality, and embo-
lization procedures alone can be effective in select patients. If untreated, 24%
of Type I endoleaks resolve spontaneously, while 26% lead to AAA rupture.Prospective Multicenter International Trial of EndoAnchor Fixation
and Sealing of Aortic Endografts: Indications for Use and Early
Results in the ANCHOR Trial
William D. Jordan Jr,1 Jean Paul de Vries2 Manish Mehta3 David Varnagy4
James Joye5. 1University of Alabama at Birmingham Alabama, Ala; 2St
Antonius Hospital, Nieuwegein, The Netherlands; 3Albany Medical
College, Albany, NY; 4Florida Hospital, Orlando, FL; 5El Camino
Hospital, California, Calif
Objectives: Endograft ﬁxation and sealing are important determi-
nants of durability after endovascular abdominal aortic aneurysm repair
(EVAR). This study was undertaken to assess the safety and efﬁcacy of
EndoAnchors to augment proximal ﬁxation and sealing in a globally-
setting.
Methods: The 149 subjects have been enrolled at 23 U.S. and four
European centers over 15 months through mid-April, 2013. EndoAnchors
implanted prophylactically at initial EVAR (“PRIMARIES,” N ¼ 111; 74%)
or therapeutically for existing type Ia endoleak/migration after the index
EVAR procedure (“REVISIONS,” N ¼ 38; 26%). The primary endpoint
was successful EndoAnchor deployment without type Ia endoleak/migra-
tion over time. A conical neck was deﬁned by diameter increase >10%
over 10 mm length.
Results: The endografts used were Endurant (57; 51%), Excluder
(30; 27%), and Zenith (24; 22%) in PRIMARIES, and Excluder (7; 18%),
AneuRx (10; 26%), Talent (6; 16%), Zenith (5; 13%), Endurant (5; 13%),
and other (5; 13%) in REVISIONS. Proximal necks averaged 18.6 6
11.2 mm in length (28% #10 mm), 25.1 6 4.5 mm in diameter, with 33
6 22 degrees of angulation; 41% were conical. An average of 5.3 EndoAn-
chors were implanted in PRIMARIES and 6.2 in REVISIONS. The most
common indication for EndoAnchor use was a hostile neck in PRIMARIES
(88%) and existing type Ia endoleak in REVISIONS (76%). Procedural
success was conﬁrmed in 99% (109/110) of the PRIMARIES and 92%
(35/38) in REVISIONS. Type Ia endoleaks were absent at 1-month in
96/99 (97%) of PRIMARIES and 32/36 (89%) of REVISIONS.
Conclusions: EndoAnchor use was associated with satisfactory early
results when high-risk anatomy was encountered at an initial EVAR proce-
dure and was successful in repairing most proximal neck problems in EVAR
revisions. Long-term data will be collected to assess the effectiveness of
EndoAnchors in preventing late complications.
